US Food and Drug Administration (FDA) has awarded Fast Track designation to ImmunoGen’s lead programme mirvetuximab soravtansine for patients with platinum-resistant ovarian cancer. The designation is for patients suffering from medium to high folate […]
SMi Group Reports: The official agenda for the 5th annual Biosimilars USA conference, which is taking place on the 14thand 15th November 2018 in New Jersey, USA, has been released. SMi is proud to present […]
Johnson & Johnson subsidiary Janssen has presented its Phase 3 data for its esketamine nasal spray for treatment-resistant depression for the first time in Europe at the International College of Neuropsychopharmacology in Vienna, Austria. […]
Novartis has reported positive data from a real-world comparison study of its Jakavi (ruxolitinib) drug conducted to treat patients with polycythemia vera (PV), a rare incurable blood cancer.Jakavi is an oral inhibitor of the JAK […]
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event. There is less than 4 weeks until SMi’s 13th […]